Catheter Precision, Inc. (VTAK) - 10-K Summary for Fiscal Year Ended December 31, 2024
Business Context and Reporting Period
Company: Catheter Precision, Inc. (VTAK)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: Following a 2023 merger, the Company focuses on cardiac electrophysiology (EP) technologies. Its primary products are the VIVO System (non-invasive 3D cardiac mapping for ventricular arrhythmias) and LockeT (suture retention device for wound healing). In January 2025, the Company acquired PeriKard, LLC, a developer of pericardial access kits.
Operational Status: The Company is a smaller reporting company with 22 employees as of March 2025. It operates in a highly competitive medical device sector dominated by larger firms like Medtronic and Boston Scientific.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $420 | $442 |
| Cost of Revenues | $42 | $30 |
| Gross Profit | $378 | $412 |
| Operating Expenses | $11,621 | $78,531 |
| Net Loss | $(16,643) | $(70,572) |
| Cash and Cash Equivalents (Year-End) | $2,873 | $3,565 |
| Accumulated Deficit | $(292,352) | $(275,709) |
| Net Cash Used in Operating Activities | $(9,271) | $(20,619) |
Liquidity Update: As of March 14, 2025, cash and cash equivalents were approximately $787,000. The Company has issued $1.5 million in related-party notes due January 31, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $22,000 (5%) to $420,000. This was driven by a $214,000 decrease in VIVO System sales, partially offset by $191,000 in first-time sales of the LockeT device. The VIVO decline is attributed to the absence of large, one-time orders for disposable patches that occurred in 2023.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses dropped significantly by $5.8 million to $11.3 million. This reduction is primarily due to lower legal fees ($2.0M), professional accounting fees ($1.4M), and stock-based compensation ($1.2M) compared to the merger-heavy 2023 period.
- Goodwill Impairment: The $60.9 million goodwill impairment charge recorded in 2023 did not recur in 2024, as goodwill was fully impaired in the prior year.
- Royalty Liability: The fair value of royalties payable due to related parties increased to $9.2 million (from $7.0 million in 2023), resulting in a $2.2 million non-cash loss on the change in fair value.
- Financing Activity: The Company raised approximately $7.2 million in net proceeds during 2024 through a September public offering and an October warrant inducement offer.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of the financial statements. Current cash reserves are insufficient to fund operations and repay short-term debt due in early 2026. The Company expects to require additional financing within the next three to six months.
Outlook and Strategy:
- Product Expansion: The Company plans to expand VIVO indications to include ischemic hearts (pending FDA submission in Q2 2025) and expects CE Mark approval for LockeT in H1 2025.
- Commercialization: The Company is rebuilding its U.S. sales force and commercial infrastructure to drive adoption of VIVO and LockeT.
- Acquisition: The January 2025 acquisition of PeriKard aims to add pericardial access technology to the portfolio, with potential future royalty obligations of 10% of net sales.
Material Risks:
- Internal Controls: The Company identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties and inadequate review controls. A new CFO was hired in January 2025 to assist in remediation.
- Customer Concentration: Three customers accounted for approximately 62% of total revenues in 2024.
- Regulatory: Future growth depends on obtaining additional FDA clearances and maintaining compliance with Quality System Regulations (QSR).
- Intellectual Property: Significant royalty obligations (approx. 12% of LockeT net sales) are owed to related parties, reducing potential future profits.
Key Facts for Investor Verification
- Cash Runway: Verify the Company's ability to secure the necessary financing within the next 3-6 months to avoid insolvency or operational suspension.
- Internal Control Remediation: Monitor progress in addressing material weaknesses in financial reporting to ensure future financial statements are reliable.
- Revenue Concentration: Assess the risk associated with reliance on three major customers for the majority of revenue.
- Royalty Obligations: Confirm the impact of the ~12% royalty on LockeT sales to related parties on future gross margins.
- Regulatory Milestones: Track the status of the FDA submission for VIVO's expanded indications (ischemic hearts) and the CE Mark approval for LockeT.